Dianthus Therapeutics (NASDAQ:DNTH) Given New $130.00 Price Target at HC Wainwright

Dianthus Therapeutics (NASDAQ:DNTH) had its price objective lifted by HC Wainwright from $47.00 to $130.00 in a research report released on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock.

DNTH has been the topic of a number of other reports. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a report on Monday. Wedbush raised their target price on Dianthus Therapeutics from $46.00 to $55.00 and gave the company an “outperform” rating in a research report on Wednesday, February 11th. Truist Financial lifted their target price on Dianthus Therapeutics from $63.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, January 21st. Finally, Stifel Nicolaus set a $120.00 price target on shares of Dianthus Therapeutics in a research report on Monday. Eleven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $98.67.

Dianthus Therapeutics Stock Performance

NASDAQ:DNTH opened at $79.23 on Monday. Dianthus Therapeutics has a 52 week low of $13.36 and a 52 week high of $84.86. The firm has a 50-day moving average price of $49.17 and a two-hundred day moving average price of $41.17. The firm has a market cap of $3.42 billion, a price-to-earnings ratio of -22.77 and a beta of 1.56.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Monday, March 9th. The company reported ($1.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). The business had revenue of $0.57 million during the quarter, compared to analysts’ expectations of $0.40 million. Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%. As a group, sell-side analysts forecast that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Institutional Trading of Dianthus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Wellington Management Group LLP grew its stake in Dianthus Therapeutics by 3,366.9% in the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after buying an additional 2,503,311 shares in the last quarter. Vestal Point Capital LP grew its position in shares of Dianthus Therapeutics by 88.2% in the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after purchasing an additional 1,499,931 shares in the last quarter. State Street Corp grew its position in shares of Dianthus Therapeutics by 124.7% in the fourth quarter. State Street Corp now owns 1,507,619 shares of the company’s stock valued at $62,129,000 after purchasing an additional 836,571 shares in the last quarter. Braidwell LP bought a new stake in shares of Dianthus Therapeutics during the 3rd quarter valued at $32,859,000. Finally, Polar Capital Holdings Plc bought a new stake in shares of Dianthus Therapeutics during the 3rd quarter valued at $29,434,000. Institutional investors own 47.53% of the company’s stock.

More Dianthus Therapeutics News

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Early “GO” decision in the Phase 3 CAPTIVATE CIDP trial — interim responder analysis met the company’s GO criteria (20 confirmed responders with fewer than 40 Part A completers); company will keep the 300mg S.C. Q2W dose and plans regulator engagement, a material clinical de‑risking event and the primary catalyst for the rally. Dianthus Announces Early GO Decision
• Positive Sentiment: Analyst upgrades/price‑target increases — HC Wainwright raised its target to $130 (buy) and Truist raised its target to $110 (buy). Upgrades increase buy‑side visibility and can amplify momentum after positive trial news. Benzinga
• Neutral Sentiment: Conference call/webcast to discuss interim responder analysis — management hosted a call to provide details, giving investors more color on the result and regulator engagement plans (increases transparency but depends on call tone). Dianthus to Host Conference Call
• Neutral Sentiment: Press and valuation pieces are drawing attention — several articles are re‑evaluating DNTH’s valuation after strong share gains, which can attract momentum traders and long‑term reallocations. Investors.com Yahoo Finance
• Neutral Sentiment: Short‑interest data shows 0 shares (report appears to be an artifact) — this reported figure is not meaningful and should not be interpreted as bearish evidence.
• Negative Sentiment: Filed a proposed $400M underwritten public offering (plus up to $60M option) — large equity raises typically dilute existing holders; while proceeds can fund development and commercialization, the market often treats such filings as near‑term negative. Dianthus Announces Proposed $400M Offering
• Negative Sentiment: Q4 earnings miss — reported loss of $1.43/share vs. consensus of ~$0.98 and negative margins/ROE; weaker results can temper enthusiasm and help explain the need for a capital raise. Zacks: Q4 Loss, Miss

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.